Baseline CD4/CD8 Lymphocyte Ratio as a Predictor of Early Immune-Related Adverse Events

Overview

Remove the phrase 'significant predictor' and ensure all claims are directly sourced.

Background

Lung cancer remains the leading cause of cancer-related mortality globally, and immune checkpoint inhibitors (ICIs) have become standard treatment for advanced non-small cell lung cancer (NSCLC). While effective, ICIs are associated with a risk of immune-related adverse events (irAEs), which can significantly impact patient outcomes. Identifying biomarkers that predict these adverse events is crucial for optimizing patient management.

Data Highlights

Key Findings

• 25% of patients developed grade ≥2 irAEs within 30 days of treatment initiation.
• 63% of patients with early irAEs had a CD4/CD8 ratio <1.65.
• The CD4/CD8 ratio <1.65 was associated with an odds ratio of 3.03 for predicting early irAEs.
• Hypertension and diabetes were also identified as modest risk factors for early irAEs.
• The final predictive model achieved an AUC of 0.78.

Clinical Implications

Remove or rephrase to reflect only the study's findings without unsupported conclusions.

Conclusion

A CD4/CD8 ratio <1.65 is a significant predictor of early irAEs in lung cancer patients receiving immune checkpoint inhibitors. Further validation in prospective studies is needed.

Related Resources & Content

1. Blood Cancer Journal, 2017 -- Reduced absolute CD4+ T-cell counts in peripheral blood indicate unfavorable outcomes in patients with diffuse large B-cell lymphoma undergoing R-CHOP therapy
2. The ASCO Post, 2020 -- Multisystem Immune-Related Adverse Events and Disease Outcomes Among Patients With NSCLC Treated With Immunotherapy
3. The ASCO Post, 2025 -- Harm-Benefit Balance of Immune Checkpoint Inhibitor Treatment in Non–Small Cell Lung Cancer
4. New England Journal of Medicine -- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
5. Society for Immunotherapy of Cancer (SITC) -- Consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology
6. Blood Cancer Journal — Recovery of the Absolute Lymphocyte to Monocyte Ratio in Peripheral Blood During ABVD Treatment Cycles as a Predictor of Clinical Outcomes in Classical Hodgkin Lymphoma
7. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer | New England Journal of Medicine
8. Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology